MAFLD fibrosis score: Using routine measures to identify advanced fibrosis in metabolic-associated fatty liver disease.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Early screening may prevent fibrosis progression in metabolic-associated fatty liver disease (MAFLD).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Aliment Pharmacol Ther

Title: Alimentary pharmacology & therapeutics

Publisher: Wiley

ISSN (Electronic): 1365-2036

ISSN (Print): 0269-2813

Publication date (Electronic): Dec 2023

Volume: 58

Issue: 11-12

Affiliations

[1 ] Medical Data Analytics Centre, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.

[2 ] State Key Laboratory of Digestive Disease, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China.

[3 ] Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong, China.

[4 ] Gastroenterology and Hepatology Unit, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.

[5 ] Department of Pathology, Hospital Sultanah Bahiyah, Alor Setar, Malaysia.

[6 ] Key Laboratory of Diagnosis and Treatment for the Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, China.

[7 ] Department of Endocrinology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

[8 ] MAFLD Research Centre, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

Article

DOI: 10.1111/apt.17722

PubMed ID: 37724633

SO-VID: e53a0f82-90d7-43a3-80e1-9d6c3f456ec5

History

Data availability:

Comments

Comment on this article

scite_

Cited by 2

See all cited by